1Money is building a payments network exclusively designed for stablecoin transactions, focusing on delivering a superior user experience. This network provides instant transaction confirmation, fixed low fees paid in the stablecoin used, and native support for multiple fiat-backed currencies. It is designed for seamless interoperability with existing blockchains and wallets while maintaining high security and compliance standards.

1upHealth operates a healthcare data platform that utilizes FHIR APIs to aggregate and share clinical and claims data, ensuring compliance with CMS interoperability regulations. The platform enables secure patient-mediated data exchange, improving access to health information for patients, providers, and payers, thereby enhancing care coordination and operational efficiency.

ABK Biomedical designs and manufactures CNC‑machined, medical‑grade titanium surgical instruments with sub‑micron tolerances for orthopedics, neurosurgery, and cardiovascular procedures. The modular, ergonomically optimized tools integrate radiopaque markers and are fully ISO 13485, FDA QSR, and CE‑certified, enabling hospitals and surgical centers to perform complex interventions with greater precision and reduced procedure time.

Acacia Pharma markets FDA‑approved hospital‑grade injectables for peri‑operative care, including Barhemsys® (IV amisulpride), a selective dopamine D₂/D₃ antagonist for postoperative nausea and vomiting, and Byfavo® (IV remimazolam), an ultra‑short‑acting benzodiazepine for procedural sedation up to 30 minutes. The company is also advancing APD403, a dual‑route amisulpride formulation targeting acute and delayed chemotherapy‑induced nausea and vomiting. Its direct U.S.

The company provides flow cytometry instruments that combine multi‑laser optical detection with automated fluidics and intuitive software to deliver reproducible, high‑parameter cellular analysis with minimal operator expertise. Its modular hardware scales from benchtop units for low‑sample volumes to high‑throughput models, and includes built‑in calibration and secure cloud connectivity for consistent data management across research and clinical labs.

Aclaris Therapeutics leverages its KINect® platform to discover covalent kinase inhibitors and dual‑targeting bispecific antibodies that modulate key inflammatory signaling pathways. It advances oral, topical, and biologic candidates for immuno‑inflammatory conditions such as atopic dermatitis, asthma, COPD, and inflammatory bowel disease, and provides licensing and co‑development partnerships to pharmaceutical and biotechnology companies.

Adagene provides a dynamic precision antibody platform that combines AI‑driven discovery, computational biology, and protein motion insights to engineer multi‑purpose antibodies with novel mechanisms of action. Its proprietary formats—NEObody™, SAFEbody®, and POWERbody™—enable targeted epitope binding, conditional activation in the tumor microenvironment, and enhanced safety and efficacy for oncology therapeutics. The company partners with pharma and biotech firms to accelerate development of these engineered antibodies for solid tumors and lymphomas.

Adaptimmune creates engineered T‑cell receptor (TCR) therapies that enable patient T cells to recognize peptide‑HLA complexes derived from intracellular tumor proteins, expanding treatment options for solid‑tumor cancers. Its platform combines target discovery, affinity‑enhanced TCR design, and a pre‑clinical safety screen to produce high‑potency, highly specific candidates for oncology developers and clinicians.

Adcentrx Therapeutics develops protein conjugate therapeutics that combine the targeting precision of biologics with the efficacy of small molecule payloads to treat cancer and other life-threatening diseases. The company focuses on creating targeted therapies that enhance treatment options for patients with advanced solid tumors.

Adela develops a blood test platform that detects minimal residual disease (MRD) and monitors treatment response across various cancer types. This technology enables early identification and management of cancer, addressing the critical need for effective monitoring and recurrence prediction in oncology care.

Aelin Therapeutics offers a biotherapeutics platform utilizing pept-ins to enhance therapeutic efficacy in targeted treatments. This technology aims to improve patient outcomes by providing precise and effective solutions for complex diseases.

Aera Therapeutics utilizes a protein nanoparticle (PNP) delivery platform that self-assembles from endogenous human proteins to package and transfer nucleic acid cargo. This technology addresses the limitations of current delivery methods for genetic medicines, enabling broader therapeutic applications.

Affinia Therapeutics develops adeno-associated virus (AAV) gene therapies using its proprietary Affinia Rationally-designed Therapies (ART) platform, which employs AI and structural modeling to enhance targeting and efficacy. The company focuses on providing transformative treatments for patients with severe diseases affecting the heart and nervous system.

AmplifyMD is a telemedicine platform that connects hospitals with a network of virtual specialists across 15 medical fields, enabling efficient specialty consultations for acute and outpatient care. By consolidating telehealth services into a single, integrated platform, it reduces patient transfers by 81% and lowers 30-day readmission rates by 38%.

The startup develops clinically validated virtual reality therapeutic devices that provide on-demand, all-in-one platforms for managing acute and chronic pain. These devices enhance clinical outcomes for patients with serious health conditions by offering targeted pain relief solutions.

Ashby provides an all-in-one recruiting platform that integrates applicant tracking, scheduling, and analytics to streamline the hiring process for companies of all sizes. By automating administrative tasks and enhancing collaboration, Ashby improves candidate experience and increases hiring team productivity.

Atalanta Therapeutics is developing di-siRNA technology to utilize RNA interference for gene silencing, targeting the underlying mechanisms of neurodegenerative diseases such as Huntington's disease. This approach aims to provide effective treatment options that address the urgent need for interventions in central nervous system disorders.

Beam Therapeutics develops precision genetic medicines using base editing technology to enable targeted modifications of DNA sequences. This approach addresses the limitations of traditional gene editing methods, offering potential treatments for genetic disorders with improved accuracy and reduced off-target effects.

Benchling provides a cloud-based platform that digitizes laboratory workflows and automates data management for biotechnology research, enabling scientists to efficiently plan, record, and analyze experiments. By reducing time spent on manual data capture and enhancing collaboration, Benchling accelerates the development of biopharmaceuticals and other biotech products.

The startup develops genome editing technology that enables the cultivation of bacteria to modify and control microbiomes for therapeutic applications. This approach allows researchers to conduct precise gene editing and microbiome engineering, facilitating the development of targeted treatments for various health conditions.

BTP Automation offers an adaptive Intelligent Continuous Hotel Sourcing platform that integrates with SAP Concur to provide real-time visibility into corporate travel hotel data. This technology automates the negotiation of hotel program terms, reducing hotel spend by at least 10% while minimizing the labor required for program management.

Canary Technologies offers a digital guest journey platform that enhances hotel operations through features like mobile check-in, AI-driven guest messaging, and dynamic upselling. This technology reduces front desk workload, minimizes chargebacks by up to 90%, and increases guest satisfaction, leading to higher revenue and improved service ratings.

Carrot Fertility provides personalized fertility healthcare solutions for employers and health plans, offering services such as IVF, egg freezing, and gestational surrogacy. The platform addresses the need for accessible, culturally competent reproductive care, improving pregnancy outcomes and reducing costs through tailored support and expert guidance.

Deal Engine automates manual processes in the travel industry using AI and APIs, enabling real-time data access and customizable solutions for travel agencies and airlines. This technology eliminates inefficiencies, allowing businesses to generate new revenue streams and significantly reduce operational costs.